AEGEAN: a phase 3 trial of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC

被引：0

作者：

Schumann, C. ^{[1
]}

Heymach, J. V. ^{[2
]}

Harpole, D. ^{[3
]}

Mitsudomi, T. ^{[4
]}

Taube, J. M. ^{[5
]}

Galffy, G. ^{[6
]}

Hochmair, M. ^{[7
]}

Winder, T. ^{[8
]}

Zukov, R. ^{[9
]}

Garbaos, G. ^{[10
]}

Gao, S. ^{[11
]}

Kuroda, H. ^{[12
]}

You, J. ^{[13
]}

Lee, K. -Y. ^{[14
]}

Antonuzzo, L. ^{[15
]}

Aperghis, M. ^{[16
]}

Doherty, G. J. ^{[16
]}

Mann, H. ^{[16
]}

Fouad, T. M. ^{[17
]}

Reck, M. ^{[18
]}

Weissinger, F. ^{[19
]}

机构：

[1] Clin Allgau Kempten & Immenstadt, Thorac Surg, Kempten, Germany

[2] MD Anderson Canc Ctr, Houston, TX USA

[3] Duke Univ, Med Ctr, Durham, NC USA

[4] Kindai Univ, Fac Med, Osaka, Japan

[5] Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA

[6] Pest Cty Pulmonol Hosp, Torokbalint, Hungary

[7] Klin Floridsdorf, Vienna, Austria

[8] Landeskrankenhaus Feldkirch, Feldkirch, Austria

[9] Krasnoyarsk State Med Univ, Krasnoyarsk, Russia

[10] Fdn Estudios Clin, Santa Fe, NM USA

[11] Natl Clin Res Ctr Canc, Canc Hosp, Natl Canc Ctr, Beijing, Peoples R China

[12] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[13] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China

[14] Shuang Ho Hosp, New Taipei, Taiwan

[15] Careggi Univ Hosp, Florence, Italy

[16] AstraZeneca, Cambridge, England

[17] AstraZeneca, New York, NY USA

[18] Lung Clin Grosshansdorf, Grosshansdorf, Germany

[19] Evangel Klinikum Bethel, Bielefeld, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V47

引用

页码：8 / 9

页数：2

共 50 条

[31] Associations of ctDNA levels during neoadjuvant treatment with pathological response in patients with resectable NSCLC from the phase 3 AEGEAN trial
Gale, Davina
Zhu, Zhou
Lai, Zhongwu
Reck, Martin
Harpole, David
Taube, Janis M.
Mitsudomi, Tetsuya
Hochmair, Maximilian
Winder, Thomas
Urban, Laszlo
Rodriguez-Cid, Jeronimo
Chu, Quincy
Chaft, Jamie
Stewart, Ross
Hodgson, Darren
Doherty, Gary J.
Heymach, John V.
CANCER RESEARCH, 2024, 84 (07)
[32] Durvalumab ± Tremelimumab plus Chemotherapy as First-line Therapy for metastatic NSCLC: Results of the Phase 3 POSEIDON Study
Rawluk, J.
Johnson, M. L.
Cho, B. C.
Luft, A.
Alatorre-Alexander, J.
Geater, S. L.
Laktionov, K.
Vasiliev, A.
Kim, S. -W
Ursol, G.
Hussein, M.
Lim, F. L.
Yang, C. -T
Araujo, L. H.
Saito, H.
Reinmuth, N.
Shi, X.
Poole, L.
Medic, N.
Peters, S.
Garon, E.
Mok, T. S. K.
Thomas, M.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 102 - 103
[33] A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
Kim, Chang Gon
Hong, Min Hee
Kim, Dahee
Lee, Brian Hyohyoung
Kim, Hyunwook
Ock, Chan-Young
Kelly, Geoffrey
Bang, Yoon Ji
Kim, Gamin
Lee, Jung Eun
Kim, Chaeyeon
Kim, Se-Heon
Hong, Hyun Jun
Park, Young Min
Sim, Nam Suk
Park, Heejung
Park, Jin Woo
Lee, Chang Geol
Kim, Kyung Hwan
Park, Goeun
Jung, Inkyung
Han, Dawoon
Kim, Jong Hoon
Cha, Junha
Lee, Insuk
Kang, Mingu
Song, Heon
Oum, Chiyoon
Kim, Seulki
Kim, Sukjun
Lim, Yoojoo
Kim-Schulze, Seunghee
Merad, Miriam
Yoon, Sun Och
Kim, Hyun Je
Koh, Yoon Woo
Kim, Hye Ryun
CLINICAL CANCER RESEARCH, 2024, 30 (10) : 2097 - 2110
[34] Patients With Resectable NSCLC Undergoing Neoadjuvant Chemoimmunotherapy: To Adjuvant or Not to Adjuvant?
Wu, Peng
Li, Dongyu
Zhang, Chaoqi
Sun, Nan
He, Jie
JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (03) : e41 - e42
[35] MERMAID-1: A Phase III Study on adjuvant Therapy with Durvalumab plus Chemotherapy in resected and postoperative MRD-positive (MRD +) NSCLC-Patients
Reinmuth, N.
Peters, S.
PNEUMOLOGIE, 2021, 75 : S11 - S12
[36] Neoadjuvant Durvalumab With or Without Sub-Ablative Stereotactic Radiotherapy (SBRT) in Patients with Resectable NSCLC (NCT02904954)
Altorki, N.
Borczuk, A.
Saxena, A.
Port, J.
Stiles, B.
Lee, B.
Sanfilippo, N.
Ko, E.
Scheff, R.
Pua, B.
Gruden, J.
Christos, P.
Spinelli, C.
Gakuria, J.
Mittal, V.
Mcgraw, T.
Formenti, S.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S746 - S746
[37] ARCTIC: Durvalumab plus tremelimumab and durvalumab monotherapy vs SoC in ≥ 3L advanced NSCLC treatment
Kowalski, D. M.
Reinmuth, N.
Orlov, S. V.
Fischer, J. R.
Sugawara, S.
Mandziuk, S.
Medine, D. M.
Novello, S.
Takeda, Y.
Soo, R. A.
Park, K.
McCleod, M.
Geater, S. L.
Powell, M.
May, R.
Stockman, P.
Planchard, D.
ANNALS OF ONCOLOGY, 2018, 29
[38] MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer - a randomized, doubleblind, placebo-controlled, phase 3 study
Al-Batran, S. -E
Janjigian, Y.
Van Cutsem, E.
Muro, K.
Wainberg, Z.
Hyung, W. J.
Molena, D.
Evans, B.
Ruscica, D.
Robbins, S. H.
Negro, A.
Tabernero, J.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 218 - 218
[39] Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial
Reck, M.
Gale, D.
Harpole, D.
Taube, J. M.
Mitsudomi, T.
Hochmair, M. J.
Winder, T.
Zhu, Z.
Lai, Z.
Stewart, R.
Hodgson, D. R.
Doherty, G. J.
Heymach, J. V.
ANNALS OF ONCOLOGY, 2023, 34 : S1300 - S1300
[40] A phase Ib trial of neoadjuvant chemoradiotherapy and durvalumab (MEDI4736) for potentially resectable stage III non-small cell lung cancer (NSCLC)
Ahn, B. C.
Lee, S.
Seo, J. W.
Lee, C. Y.
Lee, J. G.
Park, S. Y.
Kim, D. J.
Lee, C. G.
Cho, J.
Yoon, H. I.
Shim, B. Y.
Cho, D. G.
Kim, S. W.
Park, H. S.
Chun, Y. J.
Hong, M. H.
Kim, H. R.
Cho, B. C.
ANNALS OF ONCOLOGY, 2019, 30 : 601 - 601

← 1 2 3 4 5 →